Please login to the form below

Not currently logged in
Email:
Password:

Takeda acquires Nycomed

Takeda Pharmaceutical Company has completed a €9.6bn takeover of Nycomed

Takeda Pharmaceutical Company has acquired Nycomed for €9.6bn on a cash-free, debt-free basis.

The boards of directors of each company unanimously approved the transaction that is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's US dermatology business.

Takeda said: "This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 mid-range plan. Takeda has its strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialisation capability."

The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease, which is expected to be a major source of revenue growth for Takeda.

19th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics